Exploration of Cardiology

Table 1. Drugs with vasospastic potential.

Drug	Disease	Clinical specialty	Receptors or mediators
Amoxicillin, amphetamine	Infection, doping	GP, ER	5-HT₁ receptors, α₁-adrenoreceptors
Aspirin high-dose	Pain, fever	GP, rheumatologist	Thromboxane A2 vasoconstriction
BB, non-selective^*	Anxiety, glaucoma	Psychiatry, ophthalmology	β₂-adrenergic receptor blockade
Bromocriptin	Hyperprolactinemia	Endocrinology	Dopamine D2, α₁-agonist
Capecitabine, 5-FU	Chemotherapy	Oncology	Increases endothelin-1, decreases NO
Cisplatin	Chemotherapy	Oncology	Endothelial dysfunction
Cocaine	Addiction	ER	α₁-adrenoreceptors
Cyclosporine	Transplant	Nephrology, transplant unit	Endothelial dysfunction
Ergot alkaloids^**	Bleeding, migraine	Obstetrics, neurology	5-HT₁ and α-adrenergic receptor
Marijuana	Addiction	ER	CB-1 and CB-2
Methacholine	Bronchial reactivity	Pneumology	Muscarinic receptor agonist
Misoprostol	Hysteroscopy	Gynecology	Prostaglandin E receptor subtype EP3
Pseudo-ephedrine	Nasal decongestion	GP	α₁-adrenoreceptors
Triptans^***	Headache	Neurology, GP	5-HT₁ B/1D receptor agonist

Return to article view

*: e.g., propranolol; **: e.g., ergotamine, dihydroergotamine; ***: e.g., sumatriptan, zolmitriptan. BB: β-blocker; 5-FU: 5-fluorouracil; CB: cannabinoid receptors; ER: emergency room; GP: general practitioner.

Declarations

Author contributions

AV, GÁ: Conceptualization, Writing—original draft, Writing—review & editing. Both authors read and approved the submitted version.

Conflicts of interest

Albert Varga, who is the Editorial Board Member of Exploration of Cardiology, had no involvement in the decision-making or review process of this manuscript. The other author declares that there are no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Bitar MA, Shantouf R, Azzoni AA, Mahmeed WA, Atallah B. Ischemia with no obstructed coronary arteries and microvascular testing procedures: a review of utility, pharmacotherapy, and current challenges. Front Cardiovasc Med. 2025;12:1523352. [DOI] [PubMed] [PMC]

Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al.; ESC Scientific Document Group. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45:3415–537. [DOI] [PubMed]

Members WC; Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021;78:2218–61. [DOI] [PubMed]

Djordjevic Dikic A, Dedic S, Boskovic N, Giga V. Coronary vasospasm testing: escape from the cath lab! Explor Cardiol. 2024;2:1–8. [DOI]

Burgess S, Cader FA, Gulati M, Sutton NR, Appelman Y, Banerjee S. Challenges in diagnosing coronary microvascular dysfunction and coronary vasospasm. Cardiovasc Revasc Med. 2025;76:17–24. [DOI] [PubMed]

Ali J, Rha S, Choi BG, Byun JK, Choi SY, Cha JA, et al. Impact of drug-eluting stent-associated coronary artery spasm on 3-year clinical outcomes: A propensity score matching analysis. Indian Heart J. 2022;74:182–6. [DOI] [PubMed] [PMC]

Kook H, Hong SJ, Yang K, Lee S, Kim J, Park CG. Comparison of nebivolol versus diltiazem in improving coronary artery spasm and quality of life in patients with hypertension and vasospastic angina: A prospective, randomized, double-blind pilot study. PLoS One. 2020;15:e0239039. [DOI] [PubMed] [PMC]

Hokimoto S, Kaikita K, Yasuda S, Tsujita K, Ishihara M, Matoba T, et al.; Japanese Circulation Society and Japanese Association of Cardiovascular Intervention and Therapeutics and Japanese College of Cardiology Joint Working Group. JCS/CVIT/JCC 2023 Guideline Focused Update on Diagnosis and Treatment of Vasospastic Angina (Coronary Spastic Angina) and Coronary Microvascular Dysfunction. Circ J. 2023;87:879–936. [DOI] [PubMed]

Kunadian V, Chieffo A, Camici PG, Berry C, Escaned J, Maas AHEM, et al. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. Eur Heart J. 2020;41:3504–20. [DOI] [PubMed] [PMC]

10.

Radhakrishna A, Burke C, Barry P, Cawley C, Cronin H. Joining forces: a complex cardio-obstetrics case report of severe ergometrine-induced vasospasm. Eur Heart J Case Rep. 2025;9:ytaf087. [DOI] [PubMed] [PMC]

11.

Hau NV, Han LTK, Minh LHN, Kiet NA, Phong TT, Duong NK, et al. A case report and literature review of myocardial infarction with nonobstructive coronary arteries (MINOCA) possibly due to acute coronary vasospasm induced by misoprostol. Front Cardiovasc Med. 2023;10:1115358. [DOI] [PubMed] [PMC]

12.

Okonkwo K, Ojha U. Vasospasm induced myocardial ischaemia secondary to sumatriptan use. BMJ Case Rep. 2020;13:e235387. [DOI] [PubMed] [PMC]

13.

Eto R, Kawano H, Suzuki A, Akashi R, Ikeda S, Maemura K. Life-threatening Vasospastic Angina Induced by Carteolol Eye Drops. Intern Med. 2023;62:2513–6. [DOI] [PubMed] [PMC]

14.

Parameswaran K, Cox G, Kitching A, Hargreave F. Coronary and laryngeal spasm provoked by methacholine inhalation. J Allergy Clin Immunol. 2001;107:392–3. [DOI] [PubMed]

15.

Balaji N, Dixit P, Adams AM, Faiz F, Ngwainmbi D, Henry G, et al. ST-Segment Elevation Myocardial Infarction Caused by 5-Fluorouracil-Related Cardiotoxicity. Cureus. 2024;16:e52864. [DOI] [PubMed] [PMC]

16.

Baskaran J, Narayanan MA, Vakhshoorzadeh J, Ahmad A, Bertog S. Marijuana-induced Coronary Vasospasm with Persistent Inter-coronary Connection: A Case Report and Review of Literature. Cureus. 2019;11:e4799. [DOI] [PubMed] [PMC]

17.

Manninger M, Perl S, Brussee H, Toth GG. Sniff of coke breaks the heart: cocaine-induced coronary vasospasm aggravated by therapeutic hypothermia and vasopressors after aborted sudden cardiac death: a case report. Eur Heart J Case Rep. 2018;2:yty041. [DOI] [PubMed] [PMC]

18.

Patel RS, Kamil SH, Bachu R, Adikey A, Ravat V, Kaur M, et al. Marijuana use and acute myocardial infarction: A systematic review of published cases in the literature. Trends Cardiovasc Med. 2020;30:298–307. [DOI] [PubMed]

19.

Prasad M, Sabbagh AE, Rihal C, Lerman A. Phentermine and Coronary Vasospasm-Induced Myocardial Infarction. Mayo Clin Proc. 2019;94:1374–7. [DOI] [PubMed]

20.

Ralota KK, Layland J. Vasospastic angina: Pathophysiology, diagnosis, and emerging therapeutic approaches. World J Cardiol. 2025;17:108594. [DOI] [PubMed] [PMC]

21.

Aghamohammadzadeh R, El-Omar SM, Rowlands D, El-Omar M. ST elevation in recovery post exercise with normal coronary arteries. BMJ Case Rep. 2019;12:e229766. [DOI] [PubMed] [PMC]

22.

Picano E, Lattanzi F, Masini M, Distante A, L’Abbate A. Aminophylline termination of dipyridamole stress as a trigger of coronary vasospasm in variant angina. Am J Cardiol. 1988;62:694–7. [DOI] [PubMed]

23.

Cortigiani L, Donelli D, Bovenzi F. Coronary vasospasm induced by aminophylline after negative dipyridamole stress echocardiography: a case report. Explor Cardiol. 2025;3:101263. [DOI]

24.

Aboukhoudir F, Rekik S. Coronary artery spasm and dobutamine stress echocardiography in patients without known coronary disease: prevalence, predictors and outcomes. Acta Cardiol. 2016;71:435–41. [DOI] [PubMed]

25.

Martínez AM, Riquelme MMPD, Ayala JML, Espín DS. Coronary vasospasm after dobutamine stress echocardiogram triggered by esmolol. Int J Cardiol. 2015;193:17–9. [DOI] [PubMed]

26.

Picano E, Pierard L, Peteiro J, Djordjevic-Dikic A, Sade LE, Cortigiani L, et al. The clinical use of stress echocardiography in chronic coronary syndromes and beyond coronary artery disease: a clinical consensus statement from the European Association of Cardiovascular Imaging of the ESC. Eur Heart J Cardiovasc Imaging. 2024;25:e65–90. [DOI] [PubMed]

27.

Om SY, Yoo S, Cho G, Kim M, Woo Y, Lee S, et al. Diagnostic and Prognostic Value of Ergonovine Echocardiography for Noninvasive Diagnosis of Coronary Vasospasm. JACC Cardiovasc Imaging. 2020;13:1875–87. [DOI] [PubMed]

28.

Kim JH, Park J, Yang Y, Lee S, Kim D, Song J, et al. Percutaneous coronary intervention in patients with documented coronary vasospasm during long-term follow-up. Heart. 2022;108:1303–9. [DOI] [PubMed]

29.

Boivin-Proulx L, Marquis-Gravel G, Rousseau-Saine N, Harel F, Jolicoeur EM, Pelletier-Galarneau M. Hyperventilation testing in the diagnosis of vasospastic angina: A clinical review and meta-analysis. Eur J Clin Invest. 2024;54:e14178. [DOI] [PubMed]

30.

Dikic AD, Dedic S, Jovanovic I, Boskovic N, Giga V, Nedeljkovic I, et al. Noninvasive evaluation of dynamic microvascular dysfunction in ischemia and no obstructive coronary artery disease patients with suspected vasospasm. J Cardiovasc Med (Hagerstown). 2024;25:123–31. [DOI] [PubMed] [PMC]